

2023 Coding and Reimbursement Guide

Varithena™ (Polidocanol injectable foam) 1%

Varithena (polidocanol injectable foam) 1% is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options.

Claims must contain the appropriate CPT/ICD-10 code(s) for the specific site of service to indicate the items and services that are furnished. The tables below contain a list of possible CPT/ICD-10 codes that may be used to bill for venous insufficiency/varicose veins. Providers should select the most appropriate code(s) and modifier(s) with the highest level of detail to describe the service(s) actually rendered.

PHYSICIAN OFFICE POSSIBLE CPT CODES AND 2023 MEDICARE NATIONAL AVERAGE PAYMENT (SITE OF SERVICE 11 NON-FACILITY/FACILITY)

As of January 1st, 2018, Varithena may be billed with one of the following CPT¹ codes listed below. Per CPT instructions, the code selected should accurately describe the service performed.

Service Provided		Physician Fee Schedule ²			
CPT® Code	CPT® Description	Non-Facility	Non-Facility	Facility	Facility
		Total RVUs	Total Payment	Total RVUs	Total Payment
36465	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (e.g., great saphenous vein, accessory saphenous vein)	39.49	\$1,338	3.48	\$115
36466	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (e.g., great saphenous vein, accessory saphenous vein), same leg	42.63	\$1,445	4.49	\$148
36470*	Injection of sclerosant; single incompetent vein (other than telangiectasia)	3.46	\$117	1.14	\$38
36471*	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg	5.98	\$203	2.23	\$74

*If the targeted vein is an extremity truncal vein and injection of non-compounded foam sclerosant with ultrasound guided compression maneuvers to guide dispersion of the injectate is performed, see 36465, 36466. Reference: AMA 2023 CPT Professional, Page 293.

POSSIBLE ICD-10-CM DIAGNOSES CODES FOR USE OF VARITHENA

Varicose Veins with Inflammation

ICD-10-CM ³	Description
I83.10	VV of unspecified lower extremity with inflammation
I83.11	VV of right lower extremity with inflammation
I83.12	VV of left lower extremity with inflammation

Varicose Veins with Pain

ICD-10-CM ³	Description
I83.811	VV of right lower extremity with pain
I83.812	VV of left lower extremity with pain
I83.813	VV of bilateral lower extremities with pain
I83.819	VV of unspecified lower extremity with pain

Varicose Veins with Other Complications

ICD-10-CM ³	Varicose Veins with Other Complications
I83.891	VV of right lower extremity with other complications
I83.892	VV of left lower extremity with other complications
I83.893	VV of bilateral lower extremity with other complications
I83.899	VV of unspecified lower extremity with other complications

Providers are required to report diagnosis codes on claims submitted for payment using the International Classification of Disease, Clinical Modification (ICD-10-CM) codes that reflect the patient's medical condition.

HOSPITAL OUTPATIENT POSSIBLE CPT CODES AND 2023 MEDICARE NATIONAL AVERAGE PAYMENT

(SITE OF SERVICE 22)

Hospitals use CPT codes to report outpatient services. Medicare assigns each CPT code to an Ambulatory Payment Classification (APC). Each APC is assigned a payment amount.

Service Provided		Hospital Outpatient		
CPT® Code	CPT® Description	Payment	APC ⁴	Status Indicator ⁵
36465	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (e.g., great saphenous vein, accessory saphenous vein)	\$1,726	5054	T
36466	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (e.g., great saphenous vein, accessory saphenous vein), same leg	\$1,726	5054	T
36470*	Injection of sclerosant; single incompetent vein (other than telangiectasia)	\$373	5052	T
36471*	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg	\$373	5052	T

*If the targeted vein is an extremity truncal vein and injection of non-compounded foam sclerosant with ultrasound guided compression maneuvers to guide dispersion of the injectate is performed, see 36465, 36466. Reference: AMA 2023 CPT Professional, Page 293.

CMS-1500 FORM

Below is an example of how Varithena could be billed on a CMS-1500 form. Prior Authorization Numbers, ICD-10-CM codes, NPIs and charged amounts may vary depending on the provider, payer, and contract. Coding 36465, 36466, 36470 or 36471 is a clinical decision dependent on the coder's interpretation of the physician's notes.

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind. 0										22. RESUBMISSION CODE		ORIGINAL REF. NO.							
A. 183 .XXX		B. _____		C. _____		D. _____		E. _____		23. PRIOR AUTHORIZATION NUMBER		221A00432							
E. _____		F. _____		G. _____		H. _____		I. _____		J. _____		K. _____							
L. _____		M. _____		N. _____		O. _____		P. _____		Q. _____		R. _____							
24. A. DATE(S) OF SERVICE		B. PLACE OF SERVICE		C. EMG		D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER		E. DIAGNOSIS POINTER		F. \$ CHARGES		G. DAYS OR UNITS		H. EPSDT Family Plan		I. ID. QUAL		J. RENDERING PROVIDER ID. #	
MM DD YY MM DD YY		SERVICE				CPT/HCPCS MODIFIER		A		1622 74		1		NPI		123456789			

SOURCES

1. Current Procedural Terminology (CPT®) Professional Edition 2023. Copyright 2022 American Medical Association. All rights reserved. 2. 2023 CMS Physician Fee Schedule. CMS-1770-F. Effective through December 31, 2023. Conversion factor \$33.8872 3. ICD-10-CM Expert for Physicians and Hospitals, 2018. AAPC publication. 4. 2023 OPPS Payment. CMS-1772-FC. Effective through December 31, 2023. 5. Status Indicators: T - Procedure or Service, Multiple Procedure Reduction Applies Paid under OPPS; separate APC payment. N - Packaged Items and Services Packaged into APC Rates Paid under OPPS; payment is packaged into payment for other services. Therefore, there is no separate APC payment.

IMPORTANT INFORMATION

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is **always** the provider's sole responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters.

Boston Scientific does not promote the use of its products outside its FDA-approved label. Payer policies will vary and should be verified before treatment for limitations on diagnosis, coding, or site of service requirements.

This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent medical judgment of the HCP.

CPT © Copyright 2021 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Directions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

INDICATIONS

Varithena (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena. See [Full Prescribing Information](#) for Varithena™. Varithena is a registered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners.



Peripheral Interventions

300 Boston Scientific Way Marlborough, MA 01752

To order product or for more information contact customer service at 1.888.272.1001.

Medical Professionals

PI.Reimbursement@bsci.com

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-1466504-AB | JAN 2023